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Abstract
Coronaviruses induce in infected cells the formation of double membrane vesicles, which are the sites of RNA replication. Not
much is known about the formation of these vesicles, although recent observations indicate an important role for the
endoplasmic reticulum in the formation of the mouse hepatitis coronavirus (MHV) replication complexes (RCs). We now show
thatMHV replication is sensitive to brefeldin A (BFA). Consistently, expression of a dominant-negative mutant of ARF1, known to
mimic the action of the drug, inhibited MHV infection profoundly. Immunofluorescence analysis and quantitative electron
microscopy demonstrated that BFA did not block the formation of RCs per se, but rather reduced their number. MHV RNA
replication was not sensitive to BFA in MDCK cells, which are known to express the BFA-resistant guanine nucleotide exchange
factor GBF1. Accordingly, individual knockdown of the Golgi-resident targets of BFA by transfection of small interfering RNAs
(siRNAs) showed that GBF1, but not BIG1 or BIG2, was critically involved in MHV RNA replication. ARF1, the cellular effector of
GBF1, also appeared to be involved in MHV replication, as siRNAs targeting this small GTPase inhibited MHV infection
significantly. Collectively, our results demonstrate that GBF1-mediated ARF1 activation is required for efficient MHV RNA
replication and reveal that the early secretory pathway and MHV replication complex formation are closely connected.
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Introduction
Viruses rely on cellular host factors for virtually all steps of their
infection cycle. However, the cellular proteins required and the
cellular pathways hijacked by viruses have hardly been elucidated.
All positive-strand RNA viruses assemble in infected cells their
replication complexes (RCs) in association with intracellular
membranes [1,2,3,4,5]. The induction of such local micro-
environments is likely advantageous for the virus, as membrane
association may facilitate the recruitment of both the viral and
cellular components involved in RNA replication. Alternatively,
membrane association may provide a shielded environment that
prevents the activation of, or protects against, antiviral host cell
responses like those mediated by interferon.
Coronaviruses belong to a family of enveloped positive-strand
RNA viruses in the order Nidovirales. Upon translation of the viral
genomic RNA, two very large polyproteins (approximately 4,000
and 7,000 amino acids) are synthesized, the autoproteolytic
cleavage products of which collectively form the RCs. These
RCs are associated with double membrane vesicles (DMVs
[6,7,8]), which appear as cytoplasmic foci when analyzed by
fluorescence light microscopy and increase in number during the
course of the infection [6,8,9,10]. It is plausible that the non-
structural viral proteins (nsps) mediate the formation of DMVs by
modifying intracellular membranes and by recruiting cellular
components to their need. Recent studies suggest the endoplasmic
reticulum (ER) to be the lipid donor compartment of the
membrane-bound coronavirus RCs [10,11,12,13], although co-
localization of nsps with markers for endosomes, Golgi and
autophagosomes has also been described [7,10,14,15,16].
Brefeldin A (BFA) is a well known fungal metabolite that
induces the redistribution of Golgi proteins into the ER [17,18],
effectively resulting in the block of transport though the secretory
pathway [19,20]. This drug inhibits the activation of ADP-
ribosylation factor (ARF) small GTPases by targeting the large
guanine nucleotide exchange factors (GEFs) GBF1 (Golgi-specific
resistance factor 1), and BIG (BFA-inhibited GEF) 1 and 2
[21,22,23]. More specifically, BFA locks ARF*GDP when bound
to GEF, thereby blocking the GEF activity at an early stage of the
reaction, prior to guanine nucleotide release [24,25]. The large
GEFs function in the ER to Golgi transport pathway [26] and
localize to the cis-(GBF1) and trans-sides (BIG1 and BIG2) of the
Golgi complex [27]. The cellular effectors of these GEFs, ARFs,
are divided into three classes: Class I (ARF1-3), Class II (ARF 4
and 5), and Class III (ARF6) [28]. Class I ARFs regulate the
assembly of coat complexes onto vesicles budding from compart-
ments along the secretory pathway and activate lipid-modifying
enzymes (reviewed in [29,30]). While the function of Class II ARFs
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remains largely unclear, the Class III ARF6 is thought to regulate
endosomal membrane traffic [31,32]. GBF1 and the BIGs are
likely to activate distinct subclasses of ARFs at specific locations in
order to regulate different types of transport routes [27].
In the field of virology, BFA has been used, besides for studying
viral protein transport and virus assembly [33,34,35,36,37,38], to
investigate the formation of RCs and RNA replication of several
positive-strand RNA viruses [39,40,41,42]. For example, poliovi-
rus RNA replication was shown to be sensitive to BFA. In the
presence of this drug, poliovirus replication sites were not formed
and RNA replication was completely blocked [41,43]. Remark-
ably, other members of the picornavirus family appeared to differ
in their sensitivity to BFA. Whereas echovirus 11 RNA replication
was strongly inhibited by BFA, RNA replication of encephalo-
myocarditis virus was not affected at all, while parechovirus 1
exhibited an intermediate sensitivity to it [44].
Relatively little is known about the host pathways involved in
coronavirus RNA replication and in RC formation. Recently, we
demonstrated the important role of the ER in the generation of the
RCs. While MHV nsp4 was localized to this organelle when
expressed alone, it was recruited to the replication complexes in
infected cells [11]. Furthermore, coronaviral replication was
inhibited when the ER export machinery was blocked by use of
the kinase inhibitor H89 or by expression of a dominant active
mutant of Sar1 [11]. Other cellular proteins and pathways are
likely to contribute to the formation of the coronavirus RCs as
well. Here, we studied the involvement of BFA-sensitive pathways
in MHV replication and RC formation. Our results demonstrate
that GBF1-mediated ARF1 activation is required for efficient
MHV RNA replication. Moreover, together with our recent
observation about the relevance of the ER in the same process, our
data reveal that the early secretory pathway and MHV replication
are intimately connected.
Results
MHV genomic RNA replication is sensitive to BFA
BFA is known to disturb membrane traffic in most cell types,
resulting in a redistribution of Golgi proteins into the ER [17,18].
We first confirmed the sensitivity of murine LR7 cells to BFA by
immunofluorescence using antibodies directed against the Golgi
protein marker GM130 [45]. Indeed, after treatment of the cells
with 5 mg/ml BFA for 1 h, the typical Golgi staining pattern of
GM130 was lost, concomitant with a reticular redistribution of the
protein marker (data not shown). Next, we tested whether MHV
infection was sensitive to BFA. Therefore, LR7 cells were
inoculated with a luciferase-expressing recombinant of MHV-
A59 (MHV-EFLM) in the presence or absence of 5 mg/ml BFA.
After 1 h, the inoculum was removed and the cells were further
incubated either in the presence or in the absence of BFA. At 7 h
p.i., the intracellular luciferase expression level was determined
relative to untreated cells. Luciferase expression was inhibited
more than 95% when BFA was present from 1–7 h p.i., whereas
BFA treatment during virus inoculation had only a minor effect on
reporter gene expression (Fig. 1A). Although this latter decrease
might have resulted in part from a reduced entry, the negative
effect of BFA on MHV replication and transcription is evident
from the profoundly impaired MHV reporter gene expression
when BFA was added post inoculation (1–7 h p.i.).
In a control experiment, the effect of BFA on Sindbis virus
replication in LR7 cells was assayed by using Sindbis pseudovirus
particles containing luciferase-expressing replicons. As described
previously [46], Sindbis virus replication was not affected by the
BFA treatment (Fig. 1A). This result indicates that the observed
effect of BFA on MHV-driven luciferase expression was not due to
non-specific drug-induced toxicity.
Although we have demonstrated in previous studies that
reporter gene expression by MHV is a reliable measure for
coronavirus replication [47], we wanted to confirm that the
reduction in luciferase expression resulted from a corresponding
decrease in viral RNA synthesis rather than from inhibition of viral
protein translation. To this end, a similar experiment as shown in
Fig. 1A was performed, in which the amount of intracellular
genomic viral RNA was determined by real-time Taqman PCR.
As for the luciferase expression levels, the amount of genomic
RNA was found to be severely reduced when BFA was added
directly after the virus inoculation (Fig. 1B), whereas a less
profound effect was observed when cells were treated during virus
inoculation. Very similar results were obtained when targeting the
Taqman PCR to a different region of the viral genome (data not
shown). To more directly check for an effect of BFA on the
translation of viral mRNAs, we performed an additional
experiment. LR7 cells were infected at high multiplicity with the
recombinant virus MHV-2aFLS, which expresses the firefly
luciferase, and subsequently transfected with a synthetic mRNA
encoding Renilla luciferase. This synthetic mRNA mimics viral
mRNAs as it contains 5’ and 3’ untranslated regions identical to
those found in the viral genome. The cells were incubated in the
presence or absence of BFA (2–6 h p.i.) after which the
intracellular Renilla and firefly luciferase expression levels were
determined. The results show that BFA treatment did not inhibit
the synthesis of Renilla luciferase from the synthetic mRNA, while
firefly luciferase expression driven by the recombinant virus was
severely affected (Fig. 1C). Renilla luciferase expression was also not
affected in the absence of a viral infection (data not shown). All
together, these results indicate that BFA inhibits MHV RNA
replication while translation of viral mRNAs is not affected.
Next, we determined the post inoculation period during which
MHV replication was most sensitive to BFA, by analyzing the
luciferase expression levels as they are a reliable measure for RNA
replication. Thus LR7 cells infected with MHV-EFLM were
treated with BFA for overlapping 2 h periods. At the end of each
incubation period the intracellular luciferase expression levels were
Author Summary
Coronaviruses are the causative agents of many respiratory
and enteric infections in humans and animals. As with all
viruses, virtually all of the steps of their infection cycle
depend on host cellular factors. As the first and most crucial
step after their entry into cells, coronaviruses assemble their
replication complexes (RCs) in associationwith characteristic,
newly induced membranous structures. The cellular path-
ways hijacked by these plus-strand RNA viruses to create
these ‘‘factories’’ have not been elucidated. Here, we study
the involvement of the secretory pathway inmouse hepatitis
coronavirus (MHV) replication by using the drug brefeldin A
(BFA), which is known to interfere with ER–Golgi membrane
traffic by inhibiting the activation of ADP-ribosylation factor
(ARF) small GTPases. Our observations show that MHV RNA
replication is sensitive to BFA. In agreement herewith we
demonstrate, by using various techniques, that the BFA-
sensitive guanidine nucleotide exchange factor GBF1 and its
downstream effector ARF1 are of critical importance for
coronavirus replication. From our results we conclude that
MHV RNA replication depends on GBF1-mediated ARF1
activation. Our study provides new insights into the close
connection betweenMHV replication and the early secretory
pathway.
MHV Replication and the Early Secretory Pathway
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determined and compared to those in mock-treated cells. The
results showed that replication was affected throughout the course
of the infection (Fig. 1D); however, the effects were most
pronounced during the early phases of infection.
ARF1-T31N inhibits MHV replication
To confirm our observation that BFA inhibits MHV replication
but also to prove that the effects of this drug are due to the
inhibition of GEF activities, we next analyzed to what extent the
expression of a dominant-negative mutant of ARF1 (T31N) would
affect MHV infection. This ARF1 mutant has a decreased affinity
for GTP and, following GDP displacement, it remains ‘nucleotide-
free’ for a longer period than wt ARF1 [48]. As a consequence,
expression of ARF1-T31N mirrors the effects of BFA [49]. In
addition to this protein, we included a constitutive-active ARF1
mutant (ARF1-Q71L), which persists in the GTP-bound state
longer than wild-type ARF, resulting in a prolonged ARF1
activation. Expression of this latter mutant is known to inhibit
transport at later steps in the secretory pathway, e.g. from vesicular
tubular clusters (VTC) to the Golgi complex and between Golgi
stacks [49]. LR7 cells were transfected with plasmids expressing
YFP fusions of either wild type ARF1, ARF1-T31N or ARF1-
Q71L. After transfection, the cells were inoculated with an RFP-
expressing MHV-A59 recombinant (MHV-RFP) that allows flow
cytometric analysis of MHV replication [11]. The percentage of
RFP-positive cells in the YFP-expressing population was deter-
mined relative to that of the wild type ARF1 expressing cells
(Fig. 1E). Overexpression of the wt ARF1 fusion protein itself did
not significantly affect MHV infection when compared to non-
transfected cells (data not shown). The results indicate that over-
expression of the dominant-negative ARF1 mutant inhibited
MHV infection profoundly, thereby confirming the results
Figure 1. BFA inhibits MHV replication in mouse LR7 cells. (A, B, D) LR7 cells were inoculated with MHV-EFLM or with Sindbis pseudovirus
particles containing a luciferase replicon and incubated with 5 mg/ml BFA during the indicated time periods. At the end of each incubation period,
virus replication was analyzed by determining the luciferase expression level (A and D) or the amount of viral genomic RNA (B) as described in the
Material and Methods. (C) LR7 cells were inoculated with MHV-2aFLS, transfected with synthetic RNA transcribed from pM5f-RL-M3, and incubated
from 2–6 h p.i. in the presence or absence of 5 mg/ml BFA. Renilla (RL) and firefly (FL) luciferase expression levels were determined in the cell lysates
at 6 h p.i. and are depicted relative to untreated samples; (E) LR7 cells were transfected with pARF1-YFP, pARF1T31N-YFP, or pARF1Q71L-YFP and
inoculated with MHV-RFP (moi of 1) 24 h later. At 18 h p.i. FACS analyses were performed as described in Materials and Methods. The percentages of
GFP/YFP positive cells that were also RFP positive were determined relative to wild type ARF1 expressing cells. The results of representative
experiments performed in triplicate are shown. Error bars indicate standard deviations.
doi:10.1371/journal.ppat.1000088.g001
MHV Replication and the Early Secretory Pathway
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obtained with BFA. In contrast, expression of the constitutive-
active mutant of ARF1 did not influence MHV replication.
BFA inhibits but does not entirely block the formation of
MHV RCs
As BFA is known to affect intracellular vesicle formation and
transport, and because MHV replicates its genome in association
with DMVs, we next investigated the effect of BFA on the assembly
of the MHV RCs. First, we checked whether the morphological
integrity of the RCs was affected in the presence of BFA. Therefore,
LR7 cells infected with MHV-A59 were treated with BFA for 30
minutes starting 5.5 h p.i. They were subsequently fixed and
processed for immunofluorescence using antibodies both against
nsp8, which served as a protein marker for theMHV replication sites
[50,51], and against the viral structural protein M, known to reside
in the Golgi [52]. The nsp8 antibody revealed the typical perinuclear
staining pattern in both treated and non treated infected cells
(Fig. 2A). In contrast, a dispersed distribution of M protein was
observed in BFA-treated cells reflecting the collapse of the Golgi,
whereas in non-treated cells the M protein showed a clear Golgi-like
staining (Fig. 2A). These results indicate that, once formed, the
replication sites are not disrupted by BFA.
Subsequently, we investigated whether BFA inhibited RC
formation early in the infection. BFA was therefore added to
LR7 cells directly after inoculation with MHV-A59 and staining
was performed at 6 h p.i using the nsp8 antibody. Although some
perinuclear staining of nsp8 could be detected in BFA-treated cells,
the number and intensity of the nsp8 containing foci were clearly
reduced when compared to non-treated cells (Fig. 2B). We next
investigated whether these nsp8 puncta represented MHV
replication sites. Therefore, we studied the ability of the nsp8 foci
to recruit the nucleocapsid protein N, a protein previously shown to
localize to the RCs [9,50]. Three parallel cultures of LR7 cells were
transfected with a plasmid coding for a MHV N-GFP fusion
protein and 24 h post transfection two of them were infected with
MHV-A59. BFA (5 mg/ml) was added to one of these latter
cultures directly after inoculation (t = 1 h p.i.). At 6 h p.i., the cells
were fixed and subsequently processed for immunofluorescence
using the anti-nsp8 antibody (Fig. 2C). As expected, N-GFP was
diffusely localized to the cytosol in non-infected cells (indicated by
an arrowhead in Fig. 2C). In contrast, when cells were infected with
MHV, this fusion protein also appeared in foci that co-localized
with nsp8 (indicated by arrows in Fig. 2C). This co-localization was
observed both in mock- and in BFA-treated cells, indicating that
the nsp8 foci that had been formed in the presence of BFA, though
decreased in number and intensity, correspond with the replication
sites. In complete agreement with the luciferase expression data
shown above, this result demonstrates that BFA inhibits, but does
not completely block, the formation of RCs.
BFA treatment reduces the number of DMVs
To study the effects of BFA on the DMVs at an ultrastructural
level, MHV-infected LR7 cells were fixed at 6 h p.i. and
embedded in Epon resin in order to be analyzed by electron
microscopy. DMVs (indicated by the asterisks in Fig. 3A) were
always seen organized in clusters often located in the perinuclear
area. The morphology and dimensions of these vesicles were
similar to those previously described for the DMVs harboring the
RCs [7,8,10,12,14,53]. Importantly, these vesicles were not
observed in mock-infected cells (data not shown). Fig. 3B shows
a close view of these DMVs, in which the translucent interior is
surrounded by a double membrane. The presence of an inner
web-like structure is most likely artificial [10].
Treatment of cells with BFA (1–6 h) led to the expected
disappearance of an apparent Golgi complex with the concomitant
expansion of the ER volume (not shown). In these cells, vesicles
with a morphology almost identical to those present in non BFA-
treated cells were observed (Fig. 3A). However, the number of
these DMVs was significantly decreased (p,0.005) in BFA-treated
cells as compared to non-treated cells (4.9 vs. 16.8 on average per
section, Fig. 3C). The reduction in the number of DMVs is likely
to be an underestimation as only EM sections were included in the
analyses in which at least one replication vesicle could be detected.
Strikingly, the double membrane of the replication vesicles was
visually more pronounced in BFA-treated cells than in untreated
cells (Fig. 3B), which might relate to the swelling of the ER
observed after BFA addition. The DMVs were slightly bigger in
the BFA-treated cells (175.4 nm +/2 7.1 compared to 152.4 nm
+/2 4.5 in non-treated cells; p,0.05; Fig. 3D), although the
significance of this latter observation is not clear at present.
Overall, our ultrastructural analysis of MHV-infected cells
confirms that treatment of cells with BFA decreased the number of
replication vesicles, consistent with the reduced viral RNA
replication in the presence of BFA.
The GEF GBF1 is required for MHV replication
To address which ARF GEFs contribute to MHV replication,
we next focused on the BFA-sensitive GEFs localized in the
secretory pathway, i.e. GBF1, BIG1 and BIG2. First, we studied
whether coronavirus replication was affected by BFA in MDCK
cells. These cells have a BFA-resistant Golgi-apparatus due to a
point mutation in GBF1 (M832L; F. van Kuppeveld, unpublished
results). However, the trans-Golgi network (TGN) and the
endocytic organelles in MDCK cells are still sensitive to BFA
[54,55,56]. MDCK cells stably expressing the CEACAM1a
receptor (MDCK(MHVR); [57]) were inoculated with MHV-
EFLM and BFA was added either during (0–1 h p.i.) or after (1–
7 h p.i.) the inoculation. The results show that MHV replication
was not affected by BFA treatment of the cells during either time
period (Fig. 4A), pointing toward a possible involvement of the
BFA-sensitive GBF1 protein in MHV replication.
To confirm that GBF1, rather than BIG1 or BIG2, is required for
MHV replication, each one of these GEFs was specifically and
singularly depleted by RNA interference before assaying MHV
replication. For each target gene, three siRNA oligos were
transfected into HeLa-CEACAM1a cells. At 72 h post transfection,
the cells were infected with the luciferase-expressing MHV-2aFLS.
Six h later, the number of viable cells and the luciferase expression
levels were determined (Fig. S1A and S1B) as described in the
Materials and Methods. In Fig. 4B the results are presented as
relative luciferase expression (RII) levels, i.e. the luciferase activity
expressed relative to mock-treated cells after correction for the
number of viable cells. Transfection of control siRNAs targeting the
housekeeping protein glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) did not change the RII, whereas siRNAs targeting firefly
luciferase reduced the RII up to 95% (p,0.05) demonstrating the
efficiency of the siRNA transfection. Importantly, down-regulation
of GBF1 resulted in a drastic inhibition of RII (p,0.05) whereas
siRNAs targeting BIG1 and BIG2 did not have a significant effect
(Fig. 4B). Almost identical results were obtained when the three
siRNA oligos for each gene were singly transfected (data not shown).
In a parallel experiment, we demonstrated that the down-regulation
of the major target of GBF1, ARF1, had a similar phenotypic effect
on MHV replication as seen for GBF1 (Fig. 4B).
To prove the specificity of our results, we performed a series of
controls. First, the specific knockdown of the respective mRNAs
after siRNA transfection was confirmed by quantitative RT-PCR
MHV Replication and the Early Secretory Pathway
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analysis. At 72 h after transfection of the siRNAs, the correspond-
ing mRNA levels for BIG1, BIG2, GBF1 and ARF1 were found to
be reduced by 73%, 74%, 75%, and 94%, respectively. The
mRNA levels were not affected after transfection of non-
corresponding siRNAs, demonstrating the specificity of the mRNA
depletion (data not shown). Second, the functional knock-down of
GBF1 and ARF1 at the protein level was demonstrated by co-
transfection of plasmids encoding GBF1-YFP and ARF1-YFP
Figure 2. Immunofluorescence analysis of MHV RCs. LR7 cells were inoculated with MHV-A59 and subsequently mock-treated (panel A, upper
row), treated with 5 mg/ml BFA from 5.5–6 h p.i. (panel A, lower row) or from 1–6 h p.i. (panel B). Immunostaining was performed using antibodies
against nsp8 (anti-nsp8) and against the M protein (anti-M). LR7 cells were transfected with pN-EGFP and subsequently mock-infected (panel C, upper
row), infected with MHV-A59 (panel C, middle row), or infected with MHV-A59 and treated with 5 mg/ml BFA from 1 to 7 h p.i. (panel C, bottom row).
At 7 h p.i., cells were fixed and an immunostaining was performed using the nsp8 antibodies. Identical confocal microscopy settings were used for
mock-treated and BFA-treated samples. Arrowheads in panel C indicate cytosolic staining; arrows indicate nsp8-positive foci.
doi:10.1371/journal.ppat.1000088.g002
MHV Replication and the Early Secretory Pathway
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together with either the GBF1- or ARF1-specific siRNAs,
respectively. This approach was chosen because of the unavail-
ability of specific anti-antibodies. Twenty-four h after transfection,
the cells were fixed and YFP-positive cells were counted. Fig. 4C
demonstrates that GBF1 and ARF1 expression are prohibited in
the presence of their specific siRNAs.
Next, we analyzed whether inhibition of MHV replication after
depletion of ARF1 coincided with a collapse of the Golgi complex
as observed after BFA treatment. Again, HeLa-CEACAM1a cells
were transfected with siRNAs targeting ARF1 and subsequently
processed for immunofluorescence at 72 h post transfection using
the GM130 antibody. In the ARF1 siRNA-transfected cells, the
Figure 3. Ultrastructural analysis of MHV-infected LR7 cells. LR7 cells were inoculated with MHV-A59 and treated with or without 5 mg/ml
BFA from 1–6 h p.i, chemically fixed and embedded with Epon resin. (A) Numerous clusters of virus-induced DMVs (indicated by *) were found in the
perinuclear region of the cell (N-nucleus; M-mitochondrion); Panel B shows a close view of DMVs, clearly demonstrating the presence of double
membranes (indicated by arrows); (C) The average number of DMVs per cell obtained by counting 20 infected cells; (D) Average DMV diameter
obtained measuring 38 of them. Error bars indicate standard error of the mean (SEM).
doi:10.1371/journal.ppat.1000088.g003
MHV Replication and the Early Secretory Pathway
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GM130 staining was indistinguishable from that in mock-treated
cells (Fig. 4D) indicating that loss of ARF1 did not lead to the
collapse of the Golgi into the ER. This is in complete accordance
with the results of Volpicelli-Daley et al. [58], who demonstrated
that ARF1 depletion alone is not sufficient to mimic the BFA effect
on the Golgi complex, but rather requires a simultaneous
depletion of ARF1 and ARF4 [58].
Having established that depletion of GBF1 or ARF1 affects MHV
replication profoundly, we studied whether the formation of the
MHV RCs was similarly affected. To this end, we performed a
similar knock down experiment in which we transfected siRNAs
targeting either ARF1 or GBF1 and subsequently infected the cells
with a recombinant MHV, which expressed an additional copy of
nsp2, now fused to GFP. The nsp2-GFP fusion protein co-localizes
with nsp8 and provides an additional marker for the RCs (data not
shown). Six hours after infection the cells were fixed and processed
for immunofluorescence with the nsp8 antibody. In mock transfected
cells, many GFP and nsp8 positive foci were observed, which largely
co-localized (Fig. 4E). In agreement with the relative luciferase
expression values shown in Fig. 4B, both in ARF1- and GBF1-
depleted cells, the number and intensity of the nsp8 positive foci was
reduced, similar to what had been observed in BFA-treated cells
(Fig 2B). Apparently, the number of MHV RCs is reduced in these
cells. Strikingly, however, it appeared that the nsp2-GFP expression
was much more affected than that of nsp8 by the depletion of either
ARF1 or GBF1, as hardly any GFP fluorescence could be detected.
While nsp8 is expressed directly from the viral genome, the nsp2-
GFP fusion protein is expressed from a subgenomic mRNA and
hence replication and transcription is required for its expression.
These results therefore indicate that not only fewer RCs are formed
in the absence of either GBF1 or ARF1, but that these RCs are also
impaired in their RNA synthesis.
In conclusion, our results demonstrate that depletion of GBF1
and ARF1 reduces MHV replication as well as the number of
Figure 4. The role of Golgi-residing GEFs in MHV replication. (A) MDCK(MHVR) cells were inoculated with MHV-EFLM and incubated with
5 mg/ml BFA during the indicated time periods. At 7 h p.i. the luciferase expression levels were determined; (B) HeLa-CEACAM1a cells were
transfected with three siRNAs directed against either GBF1, BIG1, BIG2, ARF1, firefly luciferase (luc), or GAPDH or were mock transfected (mock).
Seventy-two h post transfection, the cells were inoculated with MHV-2aFLS. At 6 h p.i., the cell viability and luciferase expression levels were
measured as described in the Materials and Methods. The graph depicts the relative luciferase expression (RII) compared to mock-treated cells after
correction for cell viability; (C) HeLa-CEACAM1a cells were transfected with plasmids pGBF1-YFP and pARF1-YFP in the presence or absence of their
corresponding siRNAs. At 24 h post transfection, the cells were fixed and the percentage of YFP-positive cells was determined; (D) HeLa-CEACAM1a
cells transfected with siRNAs targeting ARF1 and mock-transfected cells were fixed at 72 h post transfection and processed for immunostaining using
antibodies against the Golgi marker GM130. (E) HeLa-CEACAM1a cells were transfected with siRNAs directed against GBF1 or ARF1, or were mock
transfected. Seventy-two h post transfection, the cells were inoculated with MHV-nsp2GFP and at 6 h p.i. they were fixed and processed for
immunofluorescence using the nsp8 antibody. (A–C) The results of a representative experiment performed in triplicate are shown. Error bars indicate
standard deviations. (D–E) Representative images are shown.
doi:10.1371/journal.ppat.1000088.g004
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RCs. Furthermore, our results indicate that the RCs formed in the
absence of either GBF1 or Arf1 are less active. In addition,
inhibition of MHV replication is not caused by the collapse of the
Golgi apparatus per se, as in ARF1-depleted cells virus replication is
severely affected whereas the overall morphology of the Golgi
complex is unaltered.
ARF1, COPI and PLD are not recruited to the RCs
We next addressed the question whether ARF1 is recruited to
the replication sites. To this end, LR7 cells expressing wild type
ARF1 fused to YFP were infected with MHV-A59 and either fixed
at an early (4 h) or a late (7 h) time point p.i. before identifying the
replication sites by immunostaining the cells with nsp8 antibodies.
Figure 5A shows that ARF1-YFP was predominantly localized to
the Golgi apparatus (indicated by the arrowhead on the left panel
of Fig. 5A) both at 4 h p.i. and 7 h p.i. At 4 h p.i., only in a
minority of the cells co-localization between ARF1 and nsp8 was
observed (indicated by the arrows in Fig. 5A). No co-localization
could be observed in infected cells at 7 h p.i. Similar results were
obtained for GBF1 (data not shown).
Many downstream effectors of ARF1 have been described, and
the list is still growing. One of the best known functions of ARF1
involves the regulation of COPI-mediated vesicular transport. For
the BFA-sensitive poliovirus, COPI has been found to localize at the
replication vesicles [44]. To study whether a similar recruitment of
COPI to the replication vesicles occurs during MHV replication, we
determined its localization in MHV-infected cells. Thus, HeLa-
CEACAM1a cells were infected with MHV-nsp2GFP. This
recombinant virus allowed us to directly visualize the replication
vesicles without having to perform an immunostaining with the anti-
nsp8 antibodies. This was desirable as both the antibody against
acCOP (two subunits of the COPI coat) and the nsp8 antibody had
been raised in rabbits. At 7 h p.i. the cells were fixed and processed
for immunofluorescence analysis using the acCOP antibody. The
results show that, in addition to a diffuse staining throughout the cell,
COPI was primarily localized in a Golgi-like pattern (Fig. 5B). COPI
did not co-localize with the nsp2-GFP positive sites, indicating that
COPI was not recruited to the replication sites of MHV.
Another well known effector of ARF1 is phospholipase D (PLD),
a lipid-metabolizing enzyme involved in membrane dynamics and
Figure 5. ARF1 and COPI do not co-localize with the RCs. (A) LR7 cells were transfected with pARF1-YFP, pARF1T31N-YFP, or pARF1Q71L-YFP
and inoculated with MHV-A59 (moi of 1) 24 h later. At 4 h and 7 h p.i. cells were processed for immunofluorescence using antibodies against nsp8.
Arrows indicate co-localization of nsp8 with ARF1; arrowheads indicate ARF1 localizing to the Golgi complex; (B) HeLa-CEACAM1a cells were
inoculated with MHV-nsp2-GFP (moi of 1), fixed 7 h later and processed for immunofluorescence using antibodies against acCOPI.
doi:10.1371/journal.ppat.1000088.g005
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vesicular transport [59,60]. To analyze whether RCs recruit PLD,
LR7 cells were transfected with a construct expressing PLD1b
fused to GFP and subsequently infected with MHV-A59. The cells
were fixed at 7 h p.i. before identifying the replication sites by
immunostaining the cells with nsp8 antibodies. No co-localization
between the RCs and PLD1b could be observed (Fig. S2A).
Furthermore, specific inhibition of PLD by 1-butanol [61] did not
affect MHV luciferase expression compared to controls (Fig. S2B).
Further studies will be required to examine the role of other ARF1
effectors.
MHV reduces but does not block protein secretion
Finally, we studied whether normal vesicular trafficking is affected
in MHV-infected cells. To investigate this, we made use of a Gaussia
reporter gene, the protein product of which is secreted upon
expression [62,63]. Cells were transfected with a plasmid encoding
this gene under the control of a CMV promoter and subsequently
infected with either MHV-A59, mock-infected, or treated with BFA.
At 4.5 h p.i. the intracellular and extracellular levels of Gaussia
luciferase were measured. Thus, the ratio of the luciferase activity in
the cell lysate and in the culture supernatant was determined for each
condition. While in mock-infected cells almost 60% of the total
amount of Gaussia luciferase was found in the culture supernatant, in
MHV-infected cells, the amount of secreted Gaussia luciferase was
decreased about 2-fold to 30% (Fig. 6). BFA treatment inhibited, as
expected, Gaussia protein secretion almost completely. From this we
conclude that although MHV RNA replication depends on GBF1-
mediated ARF1 activation, MHV infection does not drastically
impair the secretory pathway. This result is not unexpected, as
coronaviruses require a functional secretory pathway for the release
of their progeny virions.
Discussion
RNA viruses use and manipulate cellular membranes for the
assembly of their replication and transcription structures. We and
others have shown that coronaviruses exploit the early secretory
pathway, but the way in which they do so is not understood. In this
report we have demonstrated using several different approaches
that MHV requires a functional GBF1-ARF1 pathway for efficient
RNA replication. First, we showed that MHV, but not Sindbis
virus replication is sensitive to BFA in murine LR7 cells. Second,
we observed that MHV replication is not sensitive to BFA in
MDCK cells, which contain a BFA-resistant GBF1. Third, we
showed that the specific siRNA-based knockdown of the BFA-
sensitive GEF GBF1, but not BIG1 and BIG2, strongly affects
MHV infection. Fourth, also ARF1, a downstream effector of
GBF1, appeared to be required for efficient MHV replication, as
shown by the inhibition of MHV-driven reporter gene expression
during siRNA-mediated down regulation of ARF1 as well as
during expression of an inactive ARF1 mutant.
The inhibition of coronavirus RNA replication in the presence
of BFA is either caused by direct inhibition of RC formation,
resulting in reduced RNA replication, or by inhibition of RNA
replication via another mechanism, resulting in reduced de novo
formation of RCs. Though it is difficult to distinguish between
these two scenarios, our results indicate the latter option to be most
plausible. Although BFA reduced the number of RCs, their
formation was not completely blocked as demonstrated by
immunofluorescence staining of the RCs using the nsp8 antibody
and by quantitative electron microscopy. Apparently, BFA did not
prevent the formation of RCs after translation of the incoming
genomic RNA. In addition, MHV replication was inhibited by
BFA throughout the infection. Early in infection the inhibition was
more profound than at later time points, when many transcrip-
tionally active RCs have already been formed. Furthermore, while
the inhibition of reporter gene expression in the presence of BFA,
or after depletion of either GBF1 or ARF1, is in complete
agreement with the reduced numbers of RCs, our results also
indicate that the few RCs that are formed in the absence of GBF1
or ARF1 are less active. Therefore, we hypothesize that BFA
inhibits MHV RNA replication by affecting RC maturation or
functioning rather than RC formation per se (Fig. 7).
Replication of several viruses has now been shown to be sensitive
to BFA. These viruses, which include poliovirus [39,41,43],
grapevine fanleaf nepovirus [42] and MHV (this study), all appear
to use ER-derived membranes for the formation of their RCs ([64],
[42] and [10,11,12], respectively). Strikingly, picornaviruses belong-
ing to different genera were found to differ in their sensitivity to BFA,
which was suggested to correspond with differences in the assembly
of their RCs [44]. Replication of equine arterivirus, a distant relative
of coronaviruses, was observed not to be sensitive to BFA [13], while
other nidoviruses have not been studied to date.
Unlike for poliovirus [65], ARF1 is hardly recruited to coronavirus
RCs. We therefore hypothesize that downstream effectors of GBF1-
ARF1 are involved in MHV replication. To date, more than 20
downstream effectors of ARF1 have been identified [26,66,67,68],
and each one of these might thus be somehow implicated in the
functioning of the MHV RCs. The most well known effector of
ARF1 is COPI. For picornaviruses, BFA sensitivity was suggested to
correlate with the recruitment of COPI to these sites [44]. However,
no co-localization between COPI and the MHV RCs could be
observed. This is in agreement with the almost complete absence of
ARF1 at these sites. In addition, coronavirus RCs did not co-localize
with PLD1 nor was coronavirus replication affected by inhibition of
phospholipase D, a lipid-metabolizing enzyme involved in mem-
brane dynamics and vesicular transport [59,60]. It might be that the
GBF1-ARF1 pathway simply functions to deliver lipids to the RCs.
In agreement herewith, cerulenin, an inhibitor of phospholipid
biosynthesis, severely inhibits MHV replication (C.A.M. de Haan,
unpublished results). Nonetheless, the observed inhibition of MHV
infection after BFA treatment is probably not an indirect
consequence of the collapse of the Golgi complex as, unlike BFA
treatment, ARF1 depletion did not affect the morphology of the
Golgi complex (Fig. 4D). Consistent herewith, another recent study
showed that ARF1 depletion did not affect the Golgi morphology or
protein transport [58].
Figure 6. MHV reduces but does not block protein secretion.
LR7 cells, transfected with a plasmid encoding the Gaussia gene, were
at 1 h post transfection either infected with MHV-A59 or mock-infected
or were treated with BFA. At 4.5 h p.i. Gaussia luciferase activity was
determined both in the cell lysate and in the culture supernatant. The
relative amount of luciferase present in the supernatant and the cell
lysate is depicted.
doi:10.1371/journal.ppat.1000088.g006
MHV Replication and the Early Secretory Pathway
PLoS Pathogens | www.plospathogens.org 9 June 2008 | Volume 4 | Issue 6 | e1000088
Several studies have indicated that coronavirus replication and
the ER are closely connected. Electron microscopical analyses of
infected cells showed the partial co-localization of coronavirus
replicase proteins with the soluble ER resident protein disulfide
isomerise [10], while the DMVs were often found in close
proximity to the ER and occasionally in continuous association
with it [10,12]. Furthermore, when expressed in the absence of a
coronavirus infection, the nsp3 and nsp4 proteins were inserted
into the ER and became modified by the addition of N-linked
sugars [11,69,70], whereas expression of tagged MHV nsp4 in
MHV-infected cells resulted in the recruitment of the protein to
the replication complexes [11]. In addition, coronavirus replica-
tion was inhibited when the ER export machinery was blocked by
the use of the kinase inhibitor H89 or by expression of dominant-
active mutant of the small GTPase Sar1 [11]. We now show by
using several approaches that MHV RNA replication also depends
on GBF1-mediated ARF1 activation. Apparently, an intimate
association exists between the early secretory pathway and MHV
replication. Interestingly, whereas H89 blocked RC formation
completely [11], this was not the case when the GBF1-mediated
activation of ARF1 was impaired by BFA. Rather it appears that
the RCs formed in the absence of GBF1 or ARF1 are less active,
suggesting a role for these proteins in RC maturation or
functioning (Fig. 7). Clearly, further investigations are needed to
unravel the precise mechanism by which the secretory pathway
contributes to the biogenesis of functional coronavirus RCs and to
RNA replication.
Materials and Methods
Cells and viruses
HeLa-CEACAM1a cells were generated by transfecting HeLa
cells (obtained from the MPI-CBG High-Throughput Technology
Development Studio [71]) with the expression plasmid pMHVR
[72] as described before [73]. Murine LR7 [74], HeLa-
CEACAM1a, and Madin-Darby Canine Kidney-CEACAM1a
[MDCK(MHVR); [57] cells, which all stably express the MHV
receptor mCEACAM1a, were maintained as monolayer cultures
in Dulbecco modified Eagle medium (DMEM; Cambrex)
containing 10% fetal calf serum (FCS), 100 IU of penicillin/ml,
100 mg of streptomycin/ml (all from Life Technologies), and
0.5 mg/ml G418 (Life Technologies, Paisley, UK).
Split cells, i.e. BHK-21 cells stably expressing Sindbis virus
structural proteins [75], were maintained in Glasgow MEM
(Invitrogen) containing 10% FCS, 100 IU of penicillin/ml, 100 mg
of streptomycin/ml, 250 mg/ml G418 and 125 mg/ml hygromycine
B (Boehringer GmbH) and used to generate Sindbis pseudovirus
particles containing a replicon expressing firefly luciferase. To this
end, the firefly luciferase gene was cloned into the pSinRep5 vector
(Invitrogen) using conventional cloning procedures. The resulting
vector was subsequently processed further according to Polo et al.
[75] to produce the pseudovirus particles.
LR7 cells were used to propagate the wild type and
recombinant MHVs (based on strain A59). The recombinant
viruses expressing the firefly luciferase gene (MHV-EFLM and
MHV-2aFLS) or the red fluorescent protein (RFP) gene have been
described before [11,47]. The recombinant virus MHV-nsp2GFP,
which expresses a nsp2-green fluorescent protein (GFP) fusion
protein, was generated in a similar way as described previously for
MHV-nsp4GFP [11]. Briefly, an nsp2-GFP fusion construct was
cloned behind an additional transcription regulation sequence into
a derivative of the RNA transcription vector pMH54 [74].
Targeted recombination to obtain the recombinant MHV-
nsp2GFP was performed as described before [74].
Antibodies and plasmids
Antibodies directed against the MHV nsp8 (anti-p22, kindly
provided by M. Denison, Vanderbilt University Medical Center,
Nashville, USA [51]), the amino terminus of the MHV M protein
(J1.3, kindly provided by J. Fleming, University of Wisconsin,
Madison, USA [76]), against acCOPI (anti-acCOPI, kindly
provided by F. Wieland, University of Heidelberg, Germany),
against GBF1 (anti-GBF1) and against the Golgi marker GM130
(anti-GM130) (the latter two from BD Transduction Laboratories,
Figure 7. Model of MHV RCs and their links to the early secretory pathway. Two major steps in the anterograde protein secretion route
(reviewed in [81]) are linked to MHV RC formation and/or RNA replication. First, transport of proteins out of the ER requires ER exit site formation
controlled by Sar1p [82,83,84]. Blocking this early step by using the drug H89 [85] or by expressing of a dominant mutant of Sar1p [86] blocks MHV
replication profoundly [11]. Next, ER exit sites develop into, or form de novo, vesicular-tubular clusters (VTCs) (also called ERGIC), for which GBF1 and
ARF1 are required. This step, which can be blocked by BFA, by expressing a dominant-negative mutant of ARF1 or by down-regulating ARF1 using
siRNAs [49], is also involved in MHV RC formation (this manuscript). However, a fully functional secretory pathway is not essential, as a dominant-
active mutant of ARF1, which blocks transport between VTCs and cis-Golgi [49], does not impair MHV replication.
doi:10.1371/journal.ppat.1000088.g007
MHV Replication and the Early Secretory Pathway
PLoS Pathogens | www.plospathogens.org 10 June 2008 | Volume 4 | Issue 6 | e1000088
San Jose, USA) were used. The conjugated secondary antibodies
were purchased from Jackson Immunoresearch Laboratories.
Plasmids containing the different ARF1 and GBF1 genes in
frame with either a GFP or a yellow fluorescent protein (YFP) tag
were obtained from G. Romero [77] and C. Jackson [78],
respectively. pGBF1-YFP and pARF1-YFP encode the wild type
proteins fused to YFP. pARF1T31N-YFP and pARF1Q71L-GFP
encode a dominant-negative and a dominant-active mutant of
ARF1 fused to YFP and GFP, respectively [49]. The pN-EGFP
plasmid, which encodes the MHV nucleocapsid (N) protein
extended at its C-terminus with GFP was constructed by cloning a
PCR fragment, specifying the N gene without its stop codon, into
pEGFP-N3 (Clontech), using conventional cloning procedures.
The plasmid encoding the Gaussia reporter gene behind a CMV
promoter was generated by replacing the EGFP gene in pEGFP-
C1 (Clontech) with the Gaussia luciferase gene from pGLuc-Basic
(New England Biolabs) using conventional cloning methods. The
viral expression plasmid pM5f-RL-M3 was generated by cloning a
synthetic DNA segment (Genscript) corresponding to the
extreme 5’ 211 nt and the extreme 3’ 401 nt of the MHV-A59
genome, separated by a NheI restriction site and flanked by a T7
promoter and a poly(A) sequence, upstream and downstream,
respectively, into pUC57. Subsequently, the coding region for
Renilla luciferase, obtained from pRLnull (Promega), was cloned
into the NheI-digested vector.
DNA transfection
Subconfluent monolayers of LR7 cells grown on coverslips in 2-
cm2 tissue culture dishes were overlaid with transfection medium
consisting of 0.2 ml of Optimem (Invitrogen) that contained 1 ml
Lipofectamine 2000 (Invitrogen) and 1 mg of DNA. After 3 hours,
the medium was replaced with DMEM containing 10% FCS. At
24 h after transfection the cells were processed further as indicated.
RNA synthesis and transfection
The plasmid pM5f-RL-M3 was linearized using a PacI
restriction site directly downstream of the poly(A) sequence, and
subsequently RNA transcripts were produced using the T7
MessageMachine Kit (Ambion) according to the manufacturer’s
instructions. Of the transcripts, 0.5 pmol of RNA was transfected
into mock- or MHV-2aFLS-inoculated LR7 cells at 1 h p.i. using
Lipofectamine 2000 (Invitrogen). Next, the cells were treated with
or without 5 mg/ml BFA from 2 h until 6 h p.i., after which the
cells were lysed and intracellular Renilla and firefly luciferase
activity was measured with the Dual-Luciferase Assay Kit
(Promega) according to the manufacturer’s protocol.
Confocal immunofluorescence microscopy
Cells were fixed using a 4% paraformaldehyde solution in
phosphate buffered saline (PBS), and subsequently permeabilized
with 0.1% Triton-X100 in PBS. Next, the cells were incubated for
1 h with the first antibody diluted in PBS containing 10% normal
goat serum. After several washing steps, the cells were incubated
with an appropriate dilution of secondary antibody in the same
buffer for 1 h. After three subsequent washing steps, the coverslips
were mounted in Fluosave (Calbiochem). The immunofluores-
cence staining was analyzed using a confocal laser-scanning
microscope (Leica). GFP/YFP and FITC were excited at 488 nm
and Cy5 at 633 nm.
Quantification of virus replication
Virus replication was quantified by determining either the virus-
driven luciferase expression levels or the amount of genomic RNA.
To this end, LR7 or MDCK(MHVR) cells were inoculated at a
multiplicity of infection (moi) of 1 with MHV-EFLM, MHV-2aFLS
or Sindbis pseudovirus particles in the presence or absence of 5 mg/
ml BFA in DMEM. After 1 h, the culture medium was replaced by
DMEM containing 10% FCS and antibiotics, again in the presence
or absence of 5 mg/ml BFA. At the indicated time points, the
luciferase expression in the cells was determined using the firefly
luciferase assay system (Promega) according to manufacturer’s
instructions and using a single-tube luminometer (Turner Designs,
TD-20/20). Alternatively, RNA was isolated from the cells using the
Qiagen RNeasy kit (Qiagen) according to the manufacturer’s
protocol. TaqMan single-tube reverse transcription-PCR (RT-
PCR) assay (PE Biosystems, Foster City, California, USA) was
performed essentially as described by de Haan et al. [79]. The
reactions were performed in triplicate according to the manufactur-
er’s instructions by using the TaqMan RT-PCR kit (PE Biosystems)
and an ABI Prism 7700 sequence detector.
Small interfering (si) RNA-mediated knockdown
experiments
siRNA duplexes targeting different sites within the coding
sequences of GBF1, BIG1, BIG2, and ARF1 were designed by and
obtained from Ambion Inc. (three siRNAs per gene; nucleotide
sequences available on request). siRNAs targeting GAPDH,
luciferase GL2+GL3, and Kif11 (all from Ambion) were taken
along as controls in each experiment. One day after seeding the
HeLa-CEACAM1a cells, they were transfected with a final
concentration of 10 nM siRNA using Oligofectamine (Invitrogen).
Seventy-two h after transfection, the cells were inoculated with
MHV-2aFLS at such a moi that approximately 10% of the mock-
treated cells became infected. At 6 h post infection (p.i.), the cell
number and viability was measured by Wst-1 assay according to
the manufacturer’s protocol (Roche Diagnostics GmbH). Subse-
quently, the medium was replaced by DMEM lacking phenol red
(Cambrex) and Steadylite HTS firefly luciferase substrate (Perkin
Elmer) was added. Luciferase expression was determined using a
luminescence plate reader (Berthold Centro LB 960). Each siRNA
experiment was performed in triplicate. For each well, luciferase
values were corrected for the cell number and viability as
determined by the Wst1 assay relative to the mock-treated cells.
To validate the functional knockdown of the targeted genes,
mRNA levels of each gene were determined after siRNA
transfection using Taqman Gene Expression Assays (Applied
Biosystems, CA, USA), according to the manufacturer’s protocol.
ARF1/GBF1 expression assay
To determine whether siRNAs targeting the ARF1 and GBF1
genes effectively depleted HeLa-CEACAM1a cells from the
corresponding proteins, a siRNA transfection experiment was
performed in which 40 ng of the plasmids encoding either ARF1-
YFP or GBF1-YFP were added to the transfection mixture
containing the corresponding siRNAs. Twenty-four h after
transfection, the cells were fixed and representative images were
taken by an automated CellWorxTM microscope (Applied
Precision) with a 106 objective.
Flow cytometry
LR7 cells transfected with pARF1-YFP, pARF1T31N-YFP, or
pARF1Q71L-GFP were inoculated with MHV-RFP (moi of 5) at
24 h post transfection. Two h p.i. 1 mM HR2 peptide [80] was
added to inhibit syncytia formation. At 18 h p.i., the cells were
collected and fixed using a 3% paraformaldehyde solution. After
two washes with PBS, the samples were analyzed employing a
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FACScaliburTM flow cytometer (Becton Dickinson) gating for
YFP/GFP-positive cells in the forward and side scatter, such that a
limited cell population with similar ARF1 expression levels was
selected. From the YFP/GFP-positive population, the fraction of
cells expressing RFP was determined.
Fixation of cells and embedding in Epon resin for
electron microscopy (EM) analysis
LR7 cells infected with MHV-A59 and treated from 1 to 6 h p.i.
with or without 5 mg/ml BFA were resuspended in 2%
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for at least
2 h at room temperature (RT). This buffer was then replaced with
fresh one and the fixation was continued overnight. Cells were
then centrifuged, washed 3 times with the 0.1 M cacodylate buffer
before being post-fixed in 1% OsO4, 1.5% ferrocyanide at 4uC for
60 min. Next, the cell pellet was washed 5 times with distilled
water and left sit in the last wash for 30 min before being
centrifuged and resuspended in warm 2% low melting point agar
(Roche, Basel, Switzerland) and immediately spun down. After
solidification of the agar on ice, the tip containing the cells was cut
into small 1 mm3 blocks. These blocks were then dehydrated by
immerging them into increasing amounts of ethanol (50%, 70%,
80%, 90%, 96% and 3 times 100%) by incubation on a rotatory
wheel for at least 15 min at RT for each step. These
amalgamations were followed by others in 1,2-propylene oxide
(Merck, Haarlem, Netherlands)-Epon resin (3:1) for 30 min, 1,2-
propylene oxide -Epon resin (1:1) for 30 min, 1,2-propylene oxide-
Epon (3:1) for 60 min and Epon resin overnight. The Epon
solution was prepared by mixing 12 g of glycid ether 100, 8 g of 2-
dodecenylsuccinic acid anhydride, 5 g of methylnadic anhydride
and 560 ml of benzyldimethylamine (all from Serva, Heidelberg,
Germany). The Epon resin was then replaced the following day
with freshly made resin and the incubation continued for 4 h at
RT. After centrifugation at 3000 rpm for 10 min, the Epon resin
was polymerized by heating the sample at 63uC for 3 days. 65–
80 nm sections were then cut using an Ultracut E ultramicrotome
(Leica Microsystems) and transferred on Formvar carbon-coated
copper grids. Sections were stained first with 6% uranyl acetate for
30 min at RT and then with a lead-citrate solution (80 mM lead
nitrate, 120 mM sodium citrate, pH 12) for 2 min before being
viewed. Analysis of EM sections was performed by using a
Jeol1010 electron microscope.
Counting and statistics of EM micrographs
DMVs were defined based on the two following morphological
criteria: the typical double membrane and the presence of the
previously described web-like structure in their proximity [10]. The
size and the number of the DMVs in control and BFA-treated cells
were determined by analyzing 60 randomly selected cell profiles.
The results were statistically analyzed with the Student’s t-test.
Gene IDs
ARF1 (GeneID 375), GBF1 (GeneID 8729), BIG1 (GeneID
10565), and BIG2 (GeneID 10564).
Supporting Information
Figure S1 The effect of depletion of Golgi-residing GEFs on
MHV replication. (A–B) HeLa-CEACAM1a cells were transfected
with three siRNAs directed against either GBF1, BIG1, BIG2,
ARF1, firefly luciferase (luc) or GAPDH, or were mock transfected
(mock). Seventy-two h post transfection, the cells were inoculated
with MHV-2aFLS. At 6 h p.i., (A) the luciferase expression levels
(RLU) and (B) the cell viability (relative to mock-treated cells) were
measured.
Found at: doi:10.1371/journal.ppat.1000088.s001 (0.31 MB TIF)
Figure S2 The role of PLD in MHV replication. (A) LR7 cells
were transfected with pPLD1 and inoculated with MHV-A59 (moi
of 1) 24 h later. At 7 h p.i. cells were processed for immunoflu-
orescence using antibodies against nsp8; (B) LR7 cells were
inoculated with MHV-2aFLS (moi 1), and at 1 h p.i. they were
either mock treated or treated with different amounts of 1-butanol
or 2-butanol, as indicated. At 6 h p.i. luciferase expression was
measured.
Found at: doi:10.1371/journal.ppat.1000088.s002 (3.24 MB TIF)
Acknowledgments
We would like to thank D. Duijsings for helpful discussions, M. Denison
and J. Fleming for providing us with the antibodies directed against the
MHV nsp8 and M protein, respectively, and G. Romero and C. Jackson
for providing the plasmids containing ARF1 and GBF1, respectively.
Author Contributions
Conceived and designed the experiments: MV FR FV PR CD. Performed
the experiments: MV MRMM ET CD. Analyzed the data: MV MRMM.
Contributed reagents/materials/analysis tools: MM FR FV PR CD. Wrote
the paper: MV.
References
1. Ahlquist P, Noueiry AO, Lee WM, Kushner DB, Dye BT (2003) Host factors in
positive-strand RNA virus genome replication. J Virol 77: 8181–8186.
2. Mackenzie J (2005) Wrapping things up about virus RNA replication. Traffic 6:
967–977.
3. Novoa RR, Calderita G, Arranz R, Fontana J, Granzow H, et al. (2005) Virus
factories: associations of cell organelles for viral replication and morphogenesis.
Biol Cell 97: 147–172.
4. Salonen A, Ahola T, Kaariainen L (2005) Viral RNA replication in association
with cellular membranes. Curr Top Microbiol Immunol 285: 139–173.
5. Buck KW (1996) Comparison of the replication of positive-stranded RNA
viruses of plants and animals. Adv Virus Res 47: 159–251.
6. Bi W, Pinon JD, Hughes S, Bonilla PJ, Holmes KV, et al. (1998) Localization of
mouse hepatitis virus open reading frame 1A derived proteins. J Neurovirol 4:
594–605.
7. Gosert R, Kanjanahaluethai A, Egger D, Bienz K, Baker SC (2002) RNA
replication of mouse hepatitis virus takes place at double-membrane vesicles.
J Virol 76: 3697–3708.
8. Shi ST, Schiller JJ, Kanjanahaluethai A, Baker SC, Oh JW, et al. (1999)
Colocalization and membrane association of murine hepatitis virus gene 1
products and De novo-synthesized viral RNA in infected cells. J Virol 73:
5957–5969.
9. Denison MR, Spaan WJ, van der Meer Y, Gibson CA, Sims AC, et al. (1999)
The putative helicase of the coronavirus mouse hepatitis virus is processed from
the replicase gene polyprotein and localizes in complexes that are active in viral
RNA synthesis. J Virol 73: 6862–6871.
10. Snijder EJ, van der Meer Y, Zevenhoven-Dobbe J, Onderwater JJ, van der
Meulen J, et al. (2006) Ultrastructure and origin of membrane vesicles associated
with the severe acute respiratory syndrome coronavirus replication complex.
J Virol 80: 5927–5940.
11. Oostra M, te Lintelo EG, Deijs M, Verheije MH, Rottier PJM, et al. (2007)
Localization and membrane topology of the coronavirus nonstructural protein 4:
involvement of the early secretory pathway in replication. JVirol.
12. Stertz S, Reichelt M, Spiegel M, Kuri T, Martinez-Sobrido L, et al. (2007) The
intracellular sites of early replication and budding of SARS-coronavirus.
Virology 361: 304–315.
13. Pedersen KW, van der Meer Y, Roos N, Snijder EJ (1999) Open reading frame
1a-encoded subunits of the arterivirus replicase induce endoplasmic reticulum-
derived double-membrane vesicles which carry the viral replication complex.
J Virol 73: 2016–2026.
14. van der Meer Y, Snijder EJ, Dobbe JC, Schleich S, Denison MR, et al. (1999)
Localization of mouse hepatitis virus nonstructural proteins and RNA synthesis
indicates a role for late endosomes in viral replication. J Virol 73: 7641–7657.
MHV Replication and the Early Secretory Pathway
PLoS Pathogens | www.plospathogens.org 12 June 2008 | Volume 4 | Issue 6 | e1000088
15. Prentice E, Jerome WG, Yoshimori T, Mizushima N, Denison MR (2004)
Coronavirus replication complex formation utilizes components of cellular
autophagy. J Biol Chem 279: 10136–10141.
16. Sims AC, Ostermann J, Denison MR (2000) Mouse hepatitis virus replicase
proteins associate with two distinct populations of intracellular membranes.
J Virol 74: 5647–5654.
17. Lippincott-Schwartz J, Yuan LC, Bonifacino JS, Klausner RD (1989) Rapid
redistribution of Golgi proteins into the ER in cells treated with brefeldin A:
evidence for membrane cycling from Golgi to ER. Cell 56: 801–813.
18. Misumi Y, Misumi Y, Miki K, Takatsuki A, Tamura G, et al. (1986) Novel
blockade by brefeldin A of intracellular transport of secretory proteins in
cultured rat hepatocytes. J Biol Chem 261: 11398–11403.
19. Garcia-Mata R, Szul T, Alvarez C, Sztul E (2003) ADP-ribosylation factor/
COPI-dependent events at the endoplasmic reticulum-Golgi interface are
regulated by the guanine nucleotide exchange factor GBF1. Mol Biol Cell 14:
2250–2261.
20. Kawamoto K, Yoshida Y, Tamaki H, Torii S, Shinotsuka C, et al. (2002) GBF1,
a guanine nucleotide exchange factor for ADP-ribosylation factors, is localized to
the cis-Golgi and involved in membrane association of the COPI coat. Traffic 3:
483–495.
21. Jackson CL, Casanova JE (2000) Turning on ARF: the Sec7 family of guanine-
nucleotide-exchange factors. Trends Cell Biol 10: 60–67.
22. Jackson CL (2004) The Sec7 Family of Arf Guanine Nucleotide Exchange
Factors Proteins and Cell Regulation: Springer Netherlands. pp 71–99.
23. Melancon P, Zhao X, Lasell TKR (2004) Large ARF GEFs of the Golgi
complex. Proteins and Cell Regulation: Springer Netherlands. pp 101–119.
24. Donaldson JG, Finazzi D, Klausner RD (1992) Brefeldin A inhibits Golgi
membrane-catalysed exchange of guanine nucleotide onto ARF protein. Nature
360: 350–352.
25. Helms JB, Rothman JE (1992) Inhibition by brefeldin A of a Golgi membrane
enzyme that catalyses exchange of guanine nucleotide bound to ARF. Nature
360: 352–354.
26. Donaldson JG, Jackson CL (2000) Regulators and effectors of the ARF GTPases.
Curr Opin Cell Biol 12: 475–482.
27. Zhao X, Lasell TK, Melancon P (2002) Localization of large ADP-ribosylation
factor-guanine nucleotide exchange factors to different Golgi compartments:
evidence for distinct functions in protein traffic. Mol Biol Cell 13: 119–133.
28. Lee FJ, Stevens LA, Hall LM, Murtagh JJ Jr, Kao YL, et al. (1994)
Characterization of class II and class III ADP-ribosylation factor genes and
proteins in Drosophila melanogaster. J Biol Chem 269: 21555–21560.
29. Bonifacino JS, Glick BS (2004) The mechanisms of vesicle budding and fusion.
Cell 116: 153–166.
30. Lee MC, Miller EA, Goldberg J, Orci L, Schekman R (2004) Bi-directional
protein transport between the ER and Golgi. Annu Rev Cell Dev Biol 20:
87–123.
31. D’Souza-Schorey C, Li G, Colombo MI, Stahl PD (1995) A regulatory role for
ARF6 in receptor-mediated endocytosis. Science 267: 1175–1178.
32. Peters PJ, Hsu VW, Ooi CE, Finazzi D, Teal SB, et al. (1995) Overexpression of
wild-type and mutant ARF1 and ARF6: distinct perturbations of nonoverlap-
ping membrane compartments. J Cell Biol 128: 1003–1017.
33. Dasgupta A, Wilson DW (2001) Evaluation of the primary effect of brefeldin A
treatment upon herpes simplex virus assembly. J Gen Virol 82: 1561–1567.
34. Irurzun A, Perez L, Carrasco L (1993) Brefeldin A blocks protein glycosylation
and RNA replication of vesicular stomatitis virus. FEBS Lett 336: 496–500.
35. Madan V, Sanz MA, Carrasco L (2005) Requirement of the vesicular system for
membrane permeabilization by Sindbis virus. Virology 332: 307–315.
36. Mirazimi A, von Bonsdorff CH, Svensson L (1996) Effect of brefeldin A on
rotavirus assembly and oligosaccharide processing. Virology 217: 554–563.
37. Opstelten DJ, Raamsman MJ, Wolfs K, Horzinek MC, Rottier PJ (1995)
Envelope glycoprotein interactions in coronavirus assembly. J Cell Biol 131:
339–349.
38. Suikkanen S, Antila M, Jaatinen A, Vihinen-Ranta M, Vuento M (2003) Release
of canine parvovirus from endocytic vesicles. Virology 316: 267–280.
39. Knox C, Moffat K, Ali S, Ryan M, Wileman T (2005) Foot-and-mouth disease
virus replication sites form next to the nucleus and close to the Golgi apparatus,
but exclude marker proteins associated with host membrane compartments.
J Gen Virol 86: 687–696.
40. Mackenzie JM, Jones MK, Westaway EG (1999) Markers for trans-Golgi
membranes and the intermediate compartment localize to induced membranes
with distinct replication functions in flavivirus-infected cells. J Virol 73:
9555–9567.
41. Maynell LA, Kirkegaard K, Klymkowsky MW (1992) Inhibition of poliovirus
RNA synthesis by brefeldin A. J Virol 66: 1985–1994.
42. Ritzenthaler C, Laporte C, Gaire F, Dunoyer P, Schmitt C, et al. (2002)
Grapevine fanleaf virus replication occurs on endoplasmic reticulum-derived
membranes. J Virol 76: 8808–8819.
43. Irurzun A, Perez L, Carrasco L (1992) Involvement of membrane traffic in the
replication of poliovirus genomes: effects of brefeldin A. Virology 191: 166–175.
44. Gazina EV, Mackenzie JM, Gorrell RJ, Anderson DA (2002) Differential
requirements for COPI coats in formation of replication complexes among three
genera of Picornaviridae. J Virol 76: 11113–11122.
45. Nakamura N, Lowe M, Levine TP, Rabouille C, Warren G (1997) The vesicle
docking protein p115 binds GM130, a cis-Golgi matrix protein, in a mitotically
regulated manner. Cell 89: 445–455.
46. Molina S, Sanz MA, Madan V, Ventoso I, Castello A, et al. (2007) Differential
inhibition of cellular and Sindbis virus translation by brefeldin A. Virology 363:
430–436.
47. de Haan CA, van Genne L, Stoop JN, Volders H, Rottier PJ (2003)
Coronaviruses as vectors: position dependence of foreign gene expression.
J Virol 77: 11312–11323.
48. Szul T, Garcia-Mata R, Brandon E, Shestopal S, Alvarez C, et al. (2005)
Dissection of membrane dynamics of the ARF-guanine nucleotide exchange
factor GBF1. Traffic 6: 374–385.
49. Dascher C, Balch WE (1994) Dominant inhibitory mutants of ARF1 block
endoplasmic reticulum to Golgi transport and trigger disassembly of the Golgi
apparatus. J Biol Chem 269: 1437–1448.
50. Bost AG, Prentice E, Denison MR (2001) Mouse hepatitis virus replicase protein
complexes are translocated to sites of M protein accumulation in the ERGIC at
late times of infection. Virology 285: 21–29.
51. Lu XT, Sims AC, Denison MR (1998) Mouse hepatitis virus 3C-like protease
cleaves a 22-kilodalton protein from the open reading frame 1a polyprotein in
virus-infected cells and in vitro. J Virol 72: 2265–2271.
52. Klumperman J, Locker JK, Meijer A, Horzinek MC, Geuze HJ, et al. (1994)
Coronavirus M proteins accumulate in the Golgi complex beyond the site of
virion budding. J Virol 68: 6523–6534.
53. David-Ferreira JF, Manaker RA (1965) An Electron Microscope Study of the
Development of a Mouse Hepatitis Virus in Tissue Culture Cells. J Cell Biol 24:
57–78.
54. Hunziker W, Whitney JA, Mellman I (1991) Selective inhibition of transcytosis
by brefeldin A in MDCK cells. Cell 67: 617–627.
55. Wagner M, Rajasekaran AK, Hanzel DK, Mayor S, Rodriguez-Boulan E (1994)
Brefeldin A causes structural and functional alterations of the trans-Golgi
network of MDCK cells. J Cell Sci 107 ( Pt 4): 933–943.
56. Wang E, Pennington JG, Goldenring JR, Hunziker W, Dunn KW (2001)
Brefeldin A rapidly disrupts plasma membrane polarity by blocking polar sorting
in common endosomes of MDCK cells. J Cell Sci 114: 3309–3321.
57. Rossen JW, Strous GJ, Horzinek MC, Rottier PJ (1997) Mouse hepatitis virus
strain A59 is released from opposite sides of different epithelial cell types. J Gen
Virol 78 ( Pt 1): 61–69.
58. Volpicelli-Daley LA, Li Y, Zhang CJ, Kahn RA (2005) Isoform-selective effects
of the depletion of ADP-ribosylation factors 1–5 on membrane traffic. Mol Biol
Cell 16: 4495–4508.
59. Jenkins GM, Frohman MA (2005) Phospholipase D: a lipid centric review. Cell
Mol Life Sci 62: 2305–2316.
60. Roth MG, Bi K, Ktistakis NT, Yu S (1999) Phospholipase D as an effector for
ADP-ribosylation factor in the regulation of vesicular traffic. Chem Phys Lipids
98: 141–152.
61. Hu T, Exton JH (2005) 1-Butanol interferes with phospholipase D1 and protein
kinase Calpha association and inhibits phospholipase D1 basal activity. Biochem
Biophys Res Commun 327: 1047–1051.
62. Badr CE, Hewett JW, Breakefield XO, Tannous BA (2007) A highly sensitive
assay for monitoring the secretory pathway and ER stress. PLoS ONE 2: e571.
doi 10.1371/journal.pone.0000571.
63. Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO (2005)
Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in
culture and in vivo. Mol Ther 11: 435–443.
64. Rust RC, Landmann L, Gosert R, Tang BL, Hong W, et al. (2001) Cellular
COPII proteins are involved in production of the vesicles that form the
poliovirus replication complex. J Virol 75: 9808–9818.
65. Belov GA, Fogg MH, Ehrenfeld E (2005) Poliovirus proteins induce membrane
association of GTPase ADP-ribosylation factor. J Virol 79: 7207–7216.
66. D’Souza-Schorey C, Chavrier P (2006) ARF proteins: roles in membrane traffic
and beyond. Nat Rev Mol Cell Biol 7: 347–358.
67. Kawasaki M, Nakayama K, Wakatsuki S (2005) Membrane recruitment of
effector proteins by Arf and Rab GTPases. Curr Opin Struct Biol 15: 681–689.
68. Nie Z, Hirsch DS, Randazzo PA (2003) Arf and its many interactors. Curr Opin
Cell Biol 15: 396–404.
69. Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, et al.
(2004) Identification of severe acute respiratory syndrome coronavirus replicase
products and characterization of papain-like protease activity. J Virol 78:
13600–13612.
70. Kanjanahaluethai A, Chen Z, Jukneliene D, Baker SC (2007) Membrane
topology of murine coronavirus replicase nonstructural protein 3. Virology 361:
391–401.
71. Pelkmans L, Fava E, Grabner H, Hannus M, Habermann B, et al. (2005)
Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated
endocytosis. Nature 436: 78–86.
72. Dveksler GS, Pensiero MN, Cardellichio CB, Williams RK, Jiang GS, et al.
(1991) Cloning of the mouse hepatitis virus (MHV) receptor: expression in
human and hamster cell lines confers susceptibility to MHV. J Virol 65:
6881–6891.
73. Wurdinger T, Verheije MH, Raaben M, Bosch BJ, de Haan CA, et al. (2005)
Targeting non-human coronaviruses to human cancer cells using a bispecific
single-chain antibody. Gene Ther 12: 1394–1404.
74. Kuo L, Godeke GJ, Raamsman MJ, Masters PS, Rottier PJ (2000) Retargeting
of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the
host cell species barrier. J Virol 74: 1393–1406.
MHV Replication and the Early Secretory Pathway
PLoS Pathogens | www.plospathogens.org 13 June 2008 | Volume 4 | Issue 6 | e1000088
75. Polo JM, Belli BA, Driver DA, Frolov I, Sherrill S, et al. (1999) Stable alphavirus
packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors.
Proc Natl Acad Sci U S A 96: 4598–4603.
76. Taguchi F, Fleming JO (1989) Comparison of six different murine coronavirus
JHM variants by monoclonal antibodies against the E2 glycoprotein. Virology
169: 233–235.
77. Vasudevan C, Han W, Tan Y, Nie Y, Li D, et al. (1998) The distribution and
translocation of the G protein ADP-ribosylation factor 1 in live cells is
determined by its GTPase activity. J Cell Sci 111 ( Pt 9): 1277–1285.
78. Niu TK, Pfeifer AC, Lippincott-Schwartz J, Jackson CL (2005) Dynamics of
GBF1, a Brefeldin A-sensitive Arf1 exchange factor at the Golgi. Mol Biol Cell
16: 1213–1222.
79. de Haan CA, Stadler K, Godeke GJ, Bosch BJ, Rottier PJ (2004) Cleavage
inhibition of the murine coronavirus spike protein by a furin-like enzyme affects
cell-cell but not virus-cell fusion. J Virol 78: 6048–6054.
80. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ (2003) The coronavirus spike
protein is a class I virus fusion protein: structural and functional characterization
of the fusion core complex. J Virol 77: 8801–8811.
81. Lippincott-Schwartz J, Roberts TH, Hirschberg K (2000) Secretory protein
trafficking and organelle dynamics in living cells. Annu Rev Cell Dev Biol 16:
557–589.
82. Orci L, Perrelet A, Ravazzola M, Wieland FT, Schekman R, et al. (1993) ‘‘BFA
bodies’’: a subcompartment of the endoplasmic reticulum. Proc Natl Acad
Sci U S A 90: 11089–11093.
83. Schekman R, Orci L (1996) Coat proteins and vesicle budding. Science 271:
1526–1533.
84. Ward TH, Polishchuk RS, Caplan S, Hirschberg K, Lippincott-Schwartz J
(2001) Maintenance of Golgi structure and function depends on the integrity of
ER export. J Cell Biol 155: 557–570.
85. Lee TH, Linstedt AD (2000) Potential role for protein kinases in regulation of
bidirectional endoplasmic reticulum-to-Golgi transport revealed by protein
kinase inhibitor H89. Mol Biol Cell 11: 2577–2590.
86. Pepperkok R, Lowe M, Burke B, Kreis TE (1998) Three distinct steps in
transport of vesicular stomatitis virus glycoprotein from the ER to the cell surface
in vivo with differential sensitivities to GTP gamma S. J Cell Sci 111 (Pt 13):
1877–1888.
MHV Replication and the Early Secretory Pathway
PLoS Pathogens | www.plospathogens.org 14 June 2008 | Volume 4 | Issue 6 | e1000088
